The FDA ( Food and Drug Administration ) has approved Neupro ( Rotigotine transdermal system ), a skin patch designed to treat symptoms of early Parkinson's disease.

Rotigotine is a drug not previously approved in the United States.
Neupro is the first transdermal patch approved for the treatment of symptoms of Parkinson's disease.

Parkinson's disease results from the loss of dopamine-producing brain cells. Rotigotine, a member of the dopamine agonist class of drugs, is delivered continuously through the skin ( transdermal ) using a silicone-based patch that is replaced every 24 hours.

The effectiveness of Neupro was demonstrated in one fixed-dose response study and two flexible-dose studies. The parallel group studies were randomized, double-blinded, and placebo-controlled, and involved 1,154 patients with early Parkinson's disease who were not taking other Parkinson's medications.

The most common side effects for Neupro included skin reactions at the patch site, dizziness, nausea, vomiting, drowsiness and insomnia, most of which are typical of this class of drugs. Other potential safety concerns include sudden onset of sleep while engaged in routine activities such as driving or operating machinery ( sleep attacks ), hallucinations, and decreased blood pressure on standing up ( postural hypotension ).

According to the Parkinson's Action Network, more than 1 million Americans live with Parkinson's disease and 60,000 new cases are diagnosed each year.
The four primary symptoms of Parkinson's are trembling in hands, arms, legs, jaw, and face ( tremor ); stiffness of the limbs and trunk ( rigidity ); slowness of movement ( bradykinesia ,); and impaired balance and coordination ( postural instability ). As these symptoms become more pronounced, patients may have difficulty walking, talking, or completing other simple tasks.

Source: FDA, 2007


XagenaMedicine2007


Link: Xapedia - Medical Encyclopedia